- As of February 13, 2017, Signal Genetics, Inc. was acquired by miRagen Therapeutics, Inc., a privately-held biopharmaceutical company, in a reverse merger transaction.
- The combined company is named Miragen Therapeutics and trades under the ticker "MGEN."
Description
Signal Genetics, Inc. is a commercial-stage, molecular diagnostic company focused on providing diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. It develops, validates and delivers diagnostic services that enable better patient-care decisions.
Address
14TH FLOOR, 667 MADISON AVE.
NEW YORK, NY 10065
United States
NEW YORK, NY 10065
United States
Key stats and ratios
| Q1 (Mar '14) | 2013 | |
| Net profit margin | -64.70% | -50.03% |
| Operating margin | -15.28% | -4.55% |
| EBITD margin | - | -6.90% |
| Return on average assets | -78.99% | -66.93% |
| Return on average equity | - | - |
| Employees | 14 |
